Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: ECL stock price vs BSX: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at BSX's multiple
Needs BSX P/E.
Implied fair value · at ECL's multiple
Needs ECL P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ECOLAB INC. · implied price per share
Bear
$44.93
Base
$57.49
Bull
$73.86
BOSTON SCIENTIFIC CORPORATION · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Procter & Gamble Company
ECL vs PG
COLGATE PALMOLIVE CO
ECL vs CL
CLOROX CO /DE/
ECL vs CLX
KIMBERLY CLARK CORP
ECL vs KMB
Abbott Laboratories
ECL vs ABT
Johnson & Johnson
ECL vs JNJ
Intuitive Surgical, Inc.
ECL vs ISRG
STRYKER CORP
ECL vs SYK
ZIMMER BIOMET HOLDINGS, INC.
ECL vs ZBH
Edwards Lifesciences Corp
ECL vs EW
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe ECL can reaccelerate growth meaningfully from 2.2% toward BSX-like levels, then hold or accumulate cautiously because the valuation premium could be sustained by a stronger growth outlook; otherwise, the data support rotating away from ECL given its 38.9x P/E and -40.2% implied downside versus the current price.
ECL trades at a clear valuation premium to BSX despite materially weaker growth. Its current P/E of 38.9x versus BSX at 23.3x, plus higher P/S, EV/EBITDA, and EV/Revenue multiples, point to a rich relative valuation that is hard to justify from the comparison set.
Supporting Metrics
